| Baseline assessment |
• Full CBC, CMP, LFTs, cardiac rhythm (ECG), and renal function.
• Review for prior radiation/chemotherapy‑related organ damage.
• Pregnancy test (women of childbearing age) and contraception counseling. |
Establish a reference point and identify patients who may be at higher risk (e.g., low platelets, hepatic/renal impairment). |
| Dose adjustments |
• Start at label‑recommended dose (1.2 mg/m² IV on day 1 of 3‑week cycle).
• Reduce dose or delay cycle if neutrophil < 1 × 10⁹/L, platelets < 75 × 10⁹/L, or ANC < 1 × 10⁹/L. |
Prevent life‑threatening marrow failure and infections. |
| Monitoring |
• CBC: at least twice a week during the first two cycles, then weekly or more often if counts trend downwards.
• LFTs and renal panel before each cycle.
• Watch for signs of cardiac strain (shortness of breath, chest pain) if the patient has pre‑existing heart disease. |
Early detection of cytopenias and organ toxicities allows prompt intervention. |
| Supportive care |
• Antiemetics (e.g., ondansetron + dexamethasone) before infusion and for the next 24 h.
• Prophylactic growth factor (filgrastim) can be considered for patients with prior grade 3/4 neutropenia or those with baseline ANC < 1.5 × 10⁹/L.
• Adequate oral/IV hydration (especially if renal impairment is present). |
Reduces nausea/vomiting, lowers infection risk, and supports renal clearance. |
| Avoid or caution with interacting drugs |
• Limit concomitant use of CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin) because lurbinectedin is metabolized by CYP3A4.
• Avoid drugs that also cause bone‑marrow suppression (e.g., other cytotoxic agents, certain antiretrovirals).
• Use caution with NSAIDs or other nephrotoxic drugs. |
Prevent additive toxicity and altered drug levels. |
| Special populations |
• Hepatic impairment: Dose reduction or longer intervals may be needed; monitor LFTs closely.
• Renal impairment: Lurbinectedin is primarily cleared hepatically, but severe renal disease may still affect elimination; dose adjustment guidelines are limited—monitor carefully.
• Pregnancy/Lactation: Category X; avoid. |
Tailors therapy to patient’s organ function and prevents teratogenicity. |
| Patient education |
• Instruct patients to report fever, sore throat, or any signs of infection immediately.
• Advise on signs of bleeding (easy bruising, gum bleeding).
• Encourage adequate nutrition, rest, and adherence to scheduled labs. |
Early detection of complications and empowers patients to stay engaged in care. |